F2R and cancer: Additional studies then discovered PAR-1 (Table 2) and PAR-2 (Table 3) expression on several cancer cell lines, including epithelial carcinomas, melanoma, glioblastoma (GBM), and sarcoma [16, 31, 37, 43–73].